✦ LIBER ✦

Early discontinuation of ribavirin in HCV-2 and HCV-3 patients responding to Peg-interferon alpha-2a and ribavirin

✍ Scribed by A. Andriulli; C. Cursaro; R. Cozzolongo; A. Iacobellis; M. R. Valvano; A. Mangia; N. Minerva; D. Bacca; M. Stanzione; A. Scuteri; G. Montalto; P. Andreone

Book ID: 108886199
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 89 KB
Volume: 16
Category: Article
ISSN: 1352-0504
DOI: 10.1111/j.1365-2893.2008.01044.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Ribavirin dosage in patients with HCV ge

Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon α-2b and ribavirin

✍ A. MANGIA; O. DALGARD; N. MINERVA; H. VERBAAN; D. BACCA; H. RING-LARSEN; M. COPE 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB

Very early prediction of response to HCV

Very early prediction of response to HCV treatment with PEG-IFN-alfa-2a and ribavirin in HIV/HCV-coinfected patients

✍ E. S. A. Araújo; H. Dahari; A. U. Neumann; N. de Paula Cavalheiro; C. E. Melo; E 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 190 KB

Influence of HCV genotype 1 subtypes on

Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha-2a plus ribavirin therapy

✍ F. Nicot; L. Alric; K. Barange; S. Métivier; J.M. Dramard; J.M. Combis; B. Casta 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 223 KB

## Abstract New factors that influence the viral response in HCV non‐genotype 2/3 patients must be identified in order to optimize anti‐HCV treatment. This multicenter prospective study evaluates the influence of HCV variability and pharmacological parameters on the virological response of these pa

Treatment of HCV infection with interfer

Treatment of HCV infection with interferon alpha-2b and ribavirin in a patient with X-linked lymphoproliferative syndrome

✍ Nicola Strnad-Trojan; Richard Linde; Janine Reichenbach; Jörg Trojan; Stefan Zeu 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 89 KB

Early identification of HCV genotype 1 p

Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy

✍ Donald M. Jensen; Timothy R. Morgan; Patrick Marcellin; Paul J. Pockros; K. Raje 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 416 KB

Approximately one third of hepatitis C virus (HCV) genotype 1 patients achieved a sustained virological response (SVR) after 24 weeks of treatment with peginterferon alpha-2a (40 kd) plus ribavirin in a randomized, multinational trial. We aimed to identify factors associated with a rapid virological

Impact of peginterferon alpha-2b and rib

Impact of peginterferon alpha-2b and ribavirin treatment on liver tissue in patients with HCV or HCV–HIV co-infection

✍ Rui Sarmento-Castro; Ana Horta; Olga Vasconcelos; Helena Coelho; Josefina Mendez 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 205 KB